VIRI Virios Therapeutics Inc.

FDA Catalyst Company
4.24
+0.37  (+10%)
Previous Close 3.87
Open 3.95
52 Week Low 3.3
52 Week High 7.45
Market Cap $35,320,854
Shares 8,330,390
Float 6,616,974
Enterprise Value $33,132,970
Volume 18,489
Av. Daily Volume 21,010
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 12/15/2021

Latest News

  1. - Enrollment Completed in FORTRESS Study with Top Line Data Expected in September 2022 -

    - Conference Call Today at 8:30 a.m. ET -

    Virios Therapeutics, Inc. (NASDAQ:VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced financial results for the first quarter ended March 31, 2022.

    Key Highlights

    • Completed enrollment in Phase 2b FORTRESS fibromyalgia study with top line results expected in September 2022
    • Targeting completion of chronic toxicology studies concurrent with FORTRESS study results in preparation for fibromyalgia Phase 3 program
    • Presented at 34th Annual Roth and Virtual H.C. Wainwright BioConnect…
    View Full Article
  2. Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its first quarter 2022 financial results will be reported on Thursday, May 12, 2022 before the open of the financial markets. Management will also host a webcast and conference call on May 12, 2022 at 8:30 a.m. ET to discuss the results and provide a corporate update.

    The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations. The live call can also be accessed by dialing 888-506-0062 (domestic) or 973-528-0011 (international) using…

    View Full Article
  3. - Top line Data from the FORTRESS Study Expected in September 2022 -

    Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that it has completed enrollment in its Phase 2b FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of Herpes Simplex Virus-1 ("HSV-1")) study, which is a randomized, double-blind evaluation of IMC-1 in patients with fibromyalgia ("FM").

    Virios' lead antiviral development candidate, orally administered IMC-1, is a novel, proprietary, fixed dose, antiviral therapy combining famciclovir and celecoxib. This dual mechanism antiviral…

    View Full Article
  4. - Top line Data from Phase 2b FORTRESS Study of IMC-1 on Track for Q3 2022 -

    - Pipeline Expanded with IMC-2 as Treatment for Long COVID to be Evaluated in New Exploratory Study Targeted to Commence in Q2 2022 -

    - Conference Call Today at 8:30 a.m. ET -

    Virios Therapeutics, Inc. (NASDAQ:VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases including fibromyalgia, today announced financial results for the fourth quarter and full year ended December 31, 2021.

    Key Highlights

    • Phase 2b FORTRESS fibromyalgia study top line results on track for Q3 2022
    • Chronic toxicology studies, required for IMC-1 Phase 3 studies, are progressing as planned and synchronized for completion…
    View Full Article
  5. Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic diseases, including fibromyalgia, announced today that its fourth quarter and full year 2021 financial results will be reported on Thursday, March 17, 2022 before the open of the financial markets. Management will also host a webcast and conference call on March 17, 2022 at 8:30 a.m. ET to discuss the results and provide a corporate update.

    The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations. The live call can also be accessed by dialing 888-506-0062 (domestic) or 973-528-0011 (international) using the…

    View Full Article
View All Virios Therapeutics Inc. News